Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2006

View Archived Issues

Novel format of a TRAIL fusion protein presented at a recent meeting

Therapeutic benefits of p38 MAP kinase inhibition for MDS

Phase IIa study under way for MEM-1003 in bipolar disorder

Two phase III studies of alfimeprase complete enrollment

MAXY-G34 for chemotherapy-induced neutropenia studied in phase I

Repros updates progress of clinical trials

Clearance for phase II trial of TroVax in late-stage breast cancer

eligen technology delivers active recombinant human growth hormone in study

Pharmos and Vela revise acquisition agreement

MAP-0004 studied for acute migraine headaches in new phase II trial

AnorMED Board recommends shareholders reject hostile Genzyme offer

RIO trials show efficacy of rimonabant in diabetic and nondiabetic overweight/obese patients

SEPI-PCI trial compares the efficacy and safety of otamixaban with UFH in PCI interventions

Multiple-dose pharmacokinetics and pharmacodynamics of AZD-6140 reported in healthy subjects

Logical Therapeutics inlicenses novel NSAID

Santhera and Juvantia collaborate on fipamezole for Parkinson's dyskinesia

Zealand raises capital for R&D

Enrollment completed in several phase III studies of ferumoxytol

Coprimary endpoints not met in phase III trial of LidoPAIN

rhThrombin offers good efficacy, better immunogenicity than bovine thrombin

NDA for CIP-Tramadol ER accepted for review

Recent patents describe new compounds for diabetes and related disorders

European orphan drug status for Neuprex in meningococcal disease

Glumetza now available in U.S.

Advisory Committee recommends against approval of Genasense in CLL

Novel nebivolol metabolites for cardiovascular disorders disclosed in recent Mylan patents

Novel compounds claimed for treatment of inflammatory disorders in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...